VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
IRLA
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
IRLAIRulya Therapeutics Inc.
$40.59$39M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksIRLABalance Sheet

IRulya Therapeutics Inc. (IRLA) Balance Sheet

9Y historyFree accessUpdated daily

The firm's financial stability is precarious, with total assets declining significantly from $180.2 million in 2023Q4 to $26.6 million by 2026Q1, while accumulated deficits have ballooned to $424.5 million.

Income StatementBalance SheetCash FlowRatios

IRLA Balance Sheet

Annual statement

IRLA Balance Sheet

IRulya Therapeutics Inc. (IRLA) balance sheet — 9-year assets, liabilities & shareholders' equity history

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17
Total Current Assets106.3M22.9M44.04M77.44M93.75M111.67M137.86M106.06M72.58M7.54M
Cash & Short-Term Investments105.24M17.75M40.78M75.06M90.18M106.8M133.82M99.86M71.72M7.34M
Cash Only39.82M5.81M6.21M20.75M44.58M69.72M66.84M51.21M24.87M7.34M
Short-Term Investments65.42M11.94M34.57M54.31M45.6M37.08M66.98M48.65M46.84M0
Accounts Receivable03.62M882K993K01.13M0000
Days Sales Outstanding----------
Inventory0000000000
Days Inventory Outstanding----------
Other Current Assets1.06M54K84K81K2.37M367K694K688K821K143K
Total Non-Current Assets175K70.63M70.44M102.76M10.16M21.55M51.6M18.31M293K181K
Property, Plant & Equipment69K1.05M813K619K684K1.43M1.1M1.33M283K122K
Fixed Asset Turnover0.00x---------
Goodwill00017.63M000000
Intangible Assets067.82M60.05M63.67M5.9M00000
Long-Term Investments234K78K78K78K3.58M19.93M50.46M16.76M00
Other Non-Current Assets106K1.68M9.51M8.47M3.58M194K39K217K10K59K
Total Assets106.47M93.52M114.48M180.2M103.91M133.23M189.47M124.37M72.88M7.72M
Asset Turnover0.00x---------
Asset Growth %-90.77%-18.3%-36.47%73.42%-22.01%-29.68%52.34%70.66%844.26%-
Total Current Liabilities7.22M43.23M7.28M9.57M3.07M14.22M17M8.89M1.46M1.76M
Accounts Payable1.45M2.22M2.9M2.03M570K4.91M3.56M3.08M495K517K
Days Payables Outstanding24.52K5.71K------3.54K4.19K
Short-Term Debt018.03M064K000000
Deferred Revenue (Current)0000000000
Other Current Liabilities5.77M12.58M308K5.13M916K180K10.79M000
Current Ratio14.72x0.53x6.05x8.09x30.55x7.85x8.11x11.93x49.82x4.28x
Quick Ratio14.72x0.53x6.05x8.09x30.55x7.85x8.11x11.93x49.82x4.28x
Cash Conversion Cycle----------
Total Non-Current Liabilities21.15M86.01M77.05M85.55M248K420K208K3.08M495K26.23M
Long-Term Debt0330K14.32M13.43M000007.17M
Capital Lease Obligations623K0394K321K0420K208K000
Deferred Tax Liabilities109K04.96M17.61M248K00000
Other Non-Current Liabilities21.15M85.68M57.38M54.19M0000019.06M
Total Liabilities28.37M129.24M84.33M95.12M3.32M14.64M17.2M8.89M1.46M28M
Total Debt018.47M14.81M13.81M453K1.16M446K007.17M
Net Debt-39.82M12.66M8.6M-6.94M-44.13M-68.56M-66.39M-51.21M-24.87M-172K
Debt / Equity0.00x-0.49x0.16x0.00x0.01x0.00x---
Debt / EBITDA-0.00x---------
Net Debt / EBITDA0.32x---------
Interest Coverage-----90.12x----12.04x-6.31x
Total Equity78.11M-35.71M30.15M85.08M100.59M118.59M172.26M115.48M71.42M-20.28M
Equity Growth %7865.72%-218.47%-64.57%-15.42%-15.17%-31.16%49.17%61.69%452.17%-
Book Value per Share6.51-142.58139.36456.98600.62798.061180.841213.51662.80-188.20
Total Shareholders' Equity78.11M-35.71M30.15M85.08M100.59M118.59M172.26M115.48M71.42M-20.28M
Common Stock1K55K44K43K36K30K29K27K22K3K
Retained Earnings-527.77M-460.45M-376.47M-319.64M-288.26M-236.6M-146.65M-69.81M-32.83M-20.35M
Treasury Stock00000000-220K0
Accumulated OCI-17K5.75M-35K3.05M-289K-79K313K60K-49K-17.18M
Minority Interest0000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Critical liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Balance Sheet Erosion Accelerates Rapidly

As reported in recent financial statements, QNCX has seen its total assets decline from $180.2 million in 2023Q4 to $26.6 million by 2026Q1, a trend that underscores the rapid depletion of resources as the company attempts to pivot its clinical focus toward skeletal therapeutics.

The consistent contraction of the asset base suggests that the company is consuming its capital reserves at a rate that outpaces its ability to generate value from its clinical pipeline. Investors should monitor whether the current asset level is sufficient to reach meaningful clinical milestones without further dilutive financing.

Liquidity Buffer Nearing Critical Threshold

Based on the 2026Q1 balance sheet, the company's cash position of $18.2 million provides a temporary reprieve, yet the current ratio of 2.92 remains highly sensitive to the timing of clinical trial expenditures and potential legacy liability settlements that could rapidly drain available liquid resources.

While the current ratio appears improved compared to the 2025Q4 low of 0.53, the underlying cash burn remains a significant concern for operational continuity. The volatility in liquidity metrics suggests that the company lacks a stable financial cushion to withstand unexpected delays in its research programs.

Equity Quality Impaired by Losses

According to historical balance sheet data, the company's equity has been severely eroded by accumulated deficits, which reached $424.5 million in 2026Q1, reflecting the persistent failure of previous clinical programs to generate any form of sustainable return on invested capital for shareholders.

The negative equity position observed in 2025Q4 highlights the extent of the value destruction associated with the company's legacy neurology assets. Future equity stability is entirely dependent on the successful clinical validation of the bone-targeting platform, which remains an unproven and highly speculative endeavor.

Goodwill Impairment Risks Remain Elevated

As indicated by the company's historical filings, the presence of significant goodwill—which peaked at $67.8 million in 2025Q4—poses a substantial risk to the balance sheet, as these non-cash assets may require further write-downs if the acquired Novosteo platform fails to meet clinical expectations.

The sudden disappearance of goodwill in 2026Q1 warrants further investigation, as it may signal a significant impairment charge or a restructuring of the asset base. Investors should be wary of the potential for additional non-cash charges that could further weaken the reported book value of the firm.

IRLA — Frequently Asked Questions

Quick answers to the most common questions about buying IRLA stock.

What are the total assets of IRulya Therapeutics Inc. (IRLA)?

As of 2025, IRulya Therapeutics Inc. (IRLA) had total assets of $93.5M including $22.9M in current assets.

How much debt does IRulya Therapeutics Inc. (IRLA) have?

IRulya Therapeutics Inc. (IRLA) carries total debt of $18.5M, offset by $17.8M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.

What is the book value or shareholders' equity of IRulya Therapeutics Inc.?

IRulya Therapeutics Inc. (IRLA) has total shareholders' equity (book value) of $-35.7M ($-142.58 book value per share). Book value represents the net worth of the company belonging to common stock holders.

What is IRulya Therapeutics Inc.'s current ratio and liquidity?

IRulya Therapeutics Inc. (IRLA) reported a current ratio of 0.53x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.